Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2012

01-06-2012 | Risk Assessment and Genetic Testing for Hereditary Breast Cancer

Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers

Authors: Brian Drohan, PhD, Constance A. Roche, MSN, RN, James C. Cusack Jr., MD, Kevin S. Hughes, MD

Published in: Annals of Surgical Oncology | Issue 6/2012

Login to get access

Abstract

Purpose and Methods

Most patients who harbor a genetic mutation for hereditary breast cancer have not been identified, despite the availability of genetic testing. Developing an effective approach to the identification of high-risk individuals is the key to preventing and/or providing early diagnosis of cancer in this patient population. This educational review addresses these issues.

Results and Discussion

Using data available on the internet, and making assumptions regarding the types and results of genetic testing, we have estimated the number of mutation carriers in the country and the number who have been tested and identified as such. Overall, our ability to fund and more effectively manage carriers is weak. A technological solution is discussed.
Literature
1.
Scheuner MT, Yoon PW, Khoury MJ. Contribution of Mendelian disorders to common chronic disease: opportunities for recognition, intervention, and prevention. Am J Med Gen. 2004;125C:50–65.CrossRef
2.
Crane RM, Raymond B. Fulfilling the potential of clinical information systems. Permanente J. 2003;7:62–7.
3.
Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–89.PubMedCrossRef
4.
Wideroff L, Vadaparampil ST, Greene, MH, et al. Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet. 2005;42:749–55.PubMedCrossRef
5.
Euhus DM. Understanding mathematical models for breast cancer risk assessment and counseling. Breast J. 2001;7:224–32.PubMedCrossRef
6.
Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62:145–58.PubMedCrossRef
7.
Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98:1457–66.PubMedCrossRef
8.
Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.PubMedCrossRef
9.
10.
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol. 1996;14:1730–6.
11.
Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–7.PubMedCrossRef
12.
Palomaki GE, McClain MR, Steinort K, Sifri R, LoPresti L, Haddow JE. Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women. Genet Med. 2006;8:161–8.PubMedCrossRef
13.
Risch HA, McLaughlin JR, Cole DEC, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700–10.PubMedCrossRef
14.
15.
Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2009;28:222–31.PubMedCrossRef
16.
17.
18.
Levy DE, Garber JE, Shields AE. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med. 2009;24:822–8.PubMedCrossRef
19.
Feero WG, Bigley MB, Brinner KM, et al. New standards and enhanced utility for family health history information in the electronic health record: an update from the American health information community’s family health history multi-stakeholder workgroup. J Am Med Inform Assoc. 2008;15:723–8.PubMedCrossRef
20.
21.
22.
Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73:643–51.PubMedCrossRef
23.
Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.PubMedCrossRef
Metadata
Title
Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers
Authors
Brian Drohan, PhD
Constance A. Roche, MSN, RN
James C. Cusack Jr., MD
Kevin S. Hughes, MD
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2257-y

Other articles of this Issue 6/2012

Annals of Surgical Oncology 6/2012 Go to the issue

Colorectal Cancer

Sentinel Lymph Node Procedure Leads to Upstaging of Patients with Resectable Colon Cancer: Results of the Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer

Hepatobiliary Tumors

Number and Tumor Size Are Not Sufficient Criteria to Select Patients for Liver Transplantation for Hepatocellular Carcinoma

Melanomas

Publication and Interpretation of Clinical Trial Results: The Need for Caution

Hepatobiliary Tumors

SIRT1 Promotes Tumorigenesis and Resistance to Chemotherapy in Hepatocellular Carcinoma and its Expression Predicts Poor Prognosis

Hepatobiliary Tumors

Evolution of Long-Term Outcome of Liver Resection for Colorectal Metastases: Analysis of Actual 5-Year Survival Rates over Two Decades

Healthcare Policy and Outcomes

The Role of Tumor Markers in the Surgical Approach of Ovarian Masses in Pediatric Age: A 10-Year Study and a Literature Review